<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>An immunoconjugate was prepared containing a <z:chebi fb="0" ids="48343">disulfide</z:chebi> linker between a murine monoclonal antibody (5E9), which recognized the human transferrin receptor, and the ribosome-inactivating protein gelonin </plain></SENT>
<SENT sid="1" pm="."><plain>This immunoconjugate was found to consist of two major species, 5E9-gelonin2 and 5E9-gelonin1, and a minor species of 5E9-gelonin3 and less than 10% of either free antibody or gelonin </plain></SENT>
<SENT sid="2" pm="."><plain>5E9-gelonin was extremely toxic in vitro to human <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cell lines expressing the 5E9 antigen, including a Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, an adult T-cell <z:hpo ids='HP_0011009'>acute</z:hpo> lymphocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo>, an <z:hpo ids='HP_0004808'>acute myelogenous leukemia</z:hpo>, a promyelocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo>, and a cervical <z:mp ids='MP_0002038'>carcinoma</z:mp> line </plain></SENT>
<SENT sid="3" pm="."><plain>A 24-hour exposure to 10(-9) M immunoconjugate killed 90-99.9% of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells, depending on the cell line </plain></SENT>
<SENT sid="4" pm="."><plain>A 5E9-negative murine <z:hpo ids='HP_0001909'>leukemia</z:hpo> was not sensitive to this conjugate </plain></SENT>
<SENT sid="5" pm="."><plain>Pharmacokinetic analysis of the disappearance of this immunoconjugate from the murine circulation revealed that it had a biphasic clearance, with an initial rapid phase with a half-life (t1/2) of 3 hours and a later, slower phase with a t1/2 of about 1 day </plain></SENT>
<SENT sid="6" pm="."><plain>Analysis of blood samples by <z:chebi fb="0" ids="8984">sodium dodecyl sulfate</z:chebi> (<z:chebi fb="26" ids="8984">SDS</z:chebi>)-<z:chebi fb="0" ids="53656">polyacrylamide</z:chebi> gel electrophoresis revealed that a substantial degree of <z:chebi fb="0" ids="48343">disulfide</z:chebi>-linker breakdown occurred in vivo and that the 5E9-gelonin2 species was cleared more rapidly than the 5E9-gelonin1 </plain></SENT>
<SENT sid="7" pm="."><plain>With use of the same clonogenic assays used to measure in vitro toxicity, biologically active immunoconjugate could be detected in murine plasma for up to 24 hours after iv administration, but the concentration of immunoconjugate by this measure was considerably less than that predicted by <z:chebi fb="26" ids="8984">SDS</z:chebi>-gel electrophoresis </plain></SENT>
<SENT sid="8" pm="."><plain>The ability to deliver immunoconjugate to <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells in vivo was studied with use of the Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> Namalwa as a xenograft in <z:mp ids='MP_0003815'>nude</z:mp> mice </plain></SENT>
<SENT sid="9" pm="."><plain>It was possible to deliver substantial amounts of immunoconjugate to Namalwa cells in xenografted <z:hpo ids='HP_0001541'>ascites</z:hpo> with direct ip inoculation; lower but significant amounts of immunoconjugate could be delivered to this xenograft after systemic iv administration, provided the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> burden was low </plain></SENT>
<SENT sid="10" pm="."><plain>The 5E9-gelonin conjugate, when administered iv at the time of ip <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> inoculation, prolonged survival of <z:mp ids='MP_0003815'>nude</z:mp> mice bearing Namalwa or other human <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> as <z:hpo ids='HP_0001541'>ascites</z:hpo> xenografts and delayed or prevented the growth of <z:hpo ids='HP_0001482'>subcutaneous nodules</z:hpo> of Namalwa in an antigen-specific fashion after a single iv injection </plain></SENT>
<SENT sid="11" pm="."><plain>Direct intratumoral administration also inhibited the growth of visible <z:hpo ids='HP_0001482'>subcutaneous nodules</z:hpo> of Namalwa </plain></SENT>
<SENT sid="12" pm="."><plain>This immunoconjugate may be useful in the treatment of human <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> </plain></SENT>
</text></document>